Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 5,484 | 533 | 4,835 |
| Samples | 1,634 | 236 | 1,385 |
| Peptides | 1,260 | 179 | 1,115 |
Function
GRIN2A · Glutamate ionotropic receptor NMDA type subunit 2A
This gene encodes a member of the glutamate-gated ion channel protein family. The encoded protein is an N-methyl-D-aspartate (NMDA) receptor subunit. NMDA receptors are both ligand-gated and voltage-dependent, and are involved in long-term potentiation, an activity-dependent increase in the efficiency of synaptic transmission thought to underlie certain kinds of memory and learning. These receptors are permeable to calcium ions, and activation results in a calcium influx into post-synaptic cells, which results in the activation of several signaling cascades. Disruption of this gene is associated with focal epilepsy and speech disorder with or without cognitive disability. Alternative splicing results in multiple transcript variants. [provided by RefSeq, May 2014].
Isoforms & Proteins
4 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 1185 amino-acid changes on canonical ENST00000330684 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in GRIN2A · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in GRIN2A – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| Melanoma | 38/210 18% | 337/1899 18% |
| T-Cell Non-Hodgkins Lymphoma | 4/26 15% | 0/0 0% |
| T-Lymphoblastic Leukemia | 6/40 15% | 0/0 0% |
| Oral Cavity Carcinoma | 7/54 13% | 0/0 0% |
| Endometrial Carcinoma | 11/42 26% | 48/612 8% |
| Non-Small Cell Lung Carcinoma | 25/304 8% | 98/1390 7% |
| Squamous Cell Lung Carcinoma | 8/57 14% | 52/810 6% |
| Small Cell Lung Carcinoma | 1/9 11% | 49/752 7% |
| Other Solid Cancers | 5/94 5% | 96/1515 6% |
| Colorectal Carcinoma | 23/143 16% | 168/3239 5% |
| Chordoma | 1/7 14% | 0/13 0% |
| Acute Myeloid Leukemia | 4/90 4% | 0/0 0% |
| Gastric Carcinoma | 10/74 14% | 73/1809 4% |
| Neuroendocrine Tumour | 14/154 9% | 17/577 3% |
| Chronic Myelogenous Leukemia | 1/25 4% | 0/0 0% |
| Esophageal Carcinoma | 0/23 0% | 23/769 3% |
| Cervical Carcinoma | 4/35 11% | 9/422 2% |
| Bladder Carcinoma | 1/58 2% | 27/956 3% |
| Adrenocortical Carcinoma | 2/3 67% | 1/112 1% |
| Germ Cell Tumour | 2/25 8% | 3/169 2% |
| Thymic Epithelial Tumor | 0/0 0% | 1/39 3% |
| Head and Neck Carcinoma | 3/85 4% | 38/1574 2% |
| Other Sarcomas | 6/69 9% | 12/699 2% |
| Esophageal Squamous Cell Carcinoma | 1/51 2% | 58/2550 2% |
| Ovarian Carcinoma | 7/109 6% | 14/998 1% |
| Ewings Sarcoma | 4/63 6% | 2/262 1% |
| Glioma | 1/52 2% | 39/2127 2% |
| Mesothelioma | 3/62 5% | 1/165 1% |
| Breast Carcinoma | 11/144 8% | 48/3264 1% |
| Plasma Cell Myeloma | 5/44 11% | 1/305 0% |
Mutation Distribution
Where GRIN2A is mutated · all tissues, split by cell line vs tissue
How many mutations in GRIN2A were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 5,484 mutations in GRIN2A
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|